|
EP0673559A1
(en)
|
1992-12-14 |
1995-09-27 |
Honeywell Inc. |
Motor system with individually controlled redundant windings
|
|
WO1995006731A2
(en)
*
|
1993-09-02 |
1995-03-09 |
Ribozyme Pharmaceuticals, Inc. |
Non-nucleotide containing enzymatic nucleic acid
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
AU9063398A
(en)
|
1997-09-12 |
1999-04-05 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
EP1178999B1
(en)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analogues
|
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
|
EP1661905B9
(en)
|
2003-08-28 |
2012-12-19 |
IMANISHI, Takeshi |
Novel artificial nucleic acids of n-o bond crosslinkage type
|
|
WO2005027962A1
(en)
|
2003-09-18 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
4’-thionucleosides and oligomeric compounds
|
|
EP1869076A2
(en)
*
|
2005-03-10 |
2007-12-26 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
６−修飾された二環式核酸類似体
|
|
EP2021008B1
(en)
*
|
2006-04-07 |
2015-12-02 |
Idera Pharmaceuticals, Inc. |
Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
|
|
EP2505649A1
(en)
*
|
2006-05-05 |
2012-10-03 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of GCGR
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
US20100190837A1
(en)
|
2007-02-15 |
2010-07-29 |
Isis Pharmaceuticals, Inc. |
5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
|
|
EP2152879B1
(en)
*
|
2007-05-01 |
2012-11-14 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of beta-catenin
|
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
EP2173760B2
(en)
|
2007-06-08 |
2015-11-04 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
CA2692579C
(en)
|
2007-07-05 |
2016-05-03 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
KR101110013B1
(ko)
*
|
2007-10-05 |
2012-02-29 |
(주)바이오니아 |
서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
|
|
ES2627745T3
(es)
|
2008-11-13 |
2017-07-31 |
Nogra Pharma Limited |
Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
|
|
HK1200484A1
(zh)
*
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
EP2895200B1
(en)
*
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
US10077443B2
(en)
*
|
2012-11-15 |
2018-09-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
EP2959000B1
(en)
*
|
2013-02-25 |
2018-08-15 |
Integrated DNA Technologies Inc. |
Naphthyl-azo modifications for antisense compounds
|
|
DK2991656T3
(da)
*
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
WO2016024205A1
(en)
*
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
|
PH12018501207B1
(en)
*
|
2015-12-21 |
2024-02-23 |
Novartis Ag |
Compositions and methods for decreasing tau expression
|
|
BR112021000308A2
(pt)
*
|
2018-07-25 |
2021-04-13 |
Ionis Pharmaceuticals, Inc. |
Compostos e métodos para redução da expressão de atxn2
|
|
US20220372489A1
(en)
*
|
2019-06-21 |
2022-11-24 |
Quralis Corporation |
Ppm1a inhibitors and methods of using same
|